Allogene Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Allogene Therapeutics, Inc. (ALLO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-257.59-327.27-340.41-182.05-316.38-184.59-211.51
Depreciation & Amortization13.6414.2014.3010.457.445.031.50
Deferred Income Tax0.440.000.000.000.00-0.33-0.12
Stock Based Compensation51.7465.9583.6080.8265.260.000.00
Change in Working Capital-24.80-15.313.90-31.9553.92-6.8812.10
Change in Accounts Payable-0.50-7.504.87-0.770.620.000.00
Change in Other Working Capital-24.30-13.812.337.1214.960.000.00
Other Operating Activities16.2680.1396.38-73.133.9646.25114.63
Net Cash from Operating Activities-200.30-237.73-220.52-184.81-115.09-137.35-44.65
Investing Activities
Capital Expenditures-0.691.525.19-21.45-65.9650.79-3.23
Acquisitions0.000.000.00-17.710.00-5.080.00
Purchases of Investments-361.48164.81-248.11185.10-439.170.000.00
Sales/Maturities of Investments437.865.62111.35202.81-439.17219.95-627.47
Other Investing Activities0.000.000.000.000.000.00-2.10
Net Cash from Investing Activities75.69163.29106.16163.66-505.12164.08-632.80
Financing Activities
Common Stock Issued114.4095.702.4611.96633.5956.00642.97
Other Financing Activities2.280.000.000.0026.200.000.00
Net Cash from Financing Activities116.6895.702.9511.96633.5958.96771.18
Summary
Net Change in Cash-7.9421.25-111.41-9.1913.3885.6993.73
Cash at Beginning of Period93.4572.20183.61192.80179.4393.730.00
Cash at End of Period85.51-233.6372.20183.61192.80179.4393.73
Free Cash Flow-200.99-239.25-225.71-206.26-181.05-188.14-47.89